Palvella Therapeutics
PVLA
180 hedge funds and large institutions have $1.64B invested in Palvella Therapeutics in 2026 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 65 increasing their positions, 30 reducing their positions, and 22 closing their positions.
276% more call options, than puts
Call options by funds: $53.5M | Put options by funds: $14.2M
195% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 22
117% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 30
60% more capital invested
Capital invested by funds: $1.02B → $1.64B (+$617M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
28.98% more ownership
Funds ownership: 82.45% → 111.44% (+29%)
29% more funds holding
Funds holding: 140 → 180 (+40)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.6M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$39M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$28.3M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$27.2M |
| 5 |
Jennison Associates
New York
|
+$26.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$40.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$27.9M |
| 3 |
FAM
Fred Alger Management
New York
|
-$13.4M |
| 4 |
Morgan Stanley
New York
|
-$9.67M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$6.92M |
PVLA Hedge Fund Activity: Q1 2026 in Review
180 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2026, worth a combined $1.64B — up 60% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new PVLA positions and 22 closed out — a net gain of 43 holders — while 65 added to existing stakes and 30 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $41.6M. The largest seller was Summit Partners Public Asset Management, exiting entirely with an estimated $40.8M sold.
- 180 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2026, up from 140 in Q4 2025.
- Funds reported $1.64B of Palvella Therapeutics stock for Q1 2026, up 60% quarter-over-quarter.
- 65 funds opened new Palvella Therapeutics positions in Q1 2026 and 22 closed out, a net change of +43 holders.
- The largest Palvella Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $41.6M added.
- The largest Palvella Therapeutics seller in Q1 2026 was Summit Partners Public Asset Management, an estimated $40.8M sold.
Based on aggregated 13F filings for Q1 2026.